“The consumer’s strong consumer capacity in the imagination is the best return on the Chinese market for several years.” Since this year, the Eimah share has grown by nearly 30 per cent in aggregate, and for the first time, the market value was over €20 billion ($218 billion), surpassing that of the Swiss pharmaceutical company, Nohua, with a record high. According to the Emancipation in 2022, the income of Aimata grew by 29 to 1.1602 billion euros, of which 21.9 per cent was recorded in Asia...